All articles tagged with #tau proteins
A new review of mostly preclinical studies links GLP-1 diabetes/weight-loss medications (e.g., semaglutide, liraglutide) to reduced amyloid-beta plaques and tau tangles in cells and animals, with only two small human trials reporting mixed results; still early evidence and larger clinical trials are needed to confirm cognitive benefits.
Specialized brain cells called tanycytes clear tau proteins from cerebrospinal fluid into the bloodstream, helping remove potentially toxic tau from the brain. In Alzheimer's disease, tanycytes are damaged and less tau moves to the blood, correlating with brain tau buildup; this reveals a potential mechanism for disease progression and a new target to boost tau clearance.
A study shows that walking 3,000 to 7,500 steps daily can significantly delay Alzheimer's symptoms and cognitive decline, especially in those at risk, by reducing tau protein buildup in the brain, highlighting the importance of small lifestyle changes for brain health.
A study published in Nature Medicine found that even modest increases in physical activity, such as walking 3,000-7,500 steps daily, can slow cognitive decline and tau protein buildup in older adults at risk for Alzheimer's, suggesting lifestyle changes may delay disease progression.
Researchers have discovered that two FDA-approved cancer drugs, letrozole and irinotecan, can reduce tau protein clumps and improve cognitive functions in mice, offering a promising new approach for Alzheimer's treatment through drug repurposing. Further studies are needed to confirm their effectiveness in humans.
A new study reveals that glycogen stored in the brain interacts with tau proteins involved in Alzheimer's disease, suggesting that boosting glycogen breakdown through enzymes like GlyP or dietary interventions could offer new therapeutic strategies for neurodegeneration. The research highlights the importance of brain sugar management in preventing or slowing Alzheimer's progression and opens avenues for potential treatments involving metabolic regulation.
Recent research suggests that a protein from the stomach bacteria Helicobacter pylori, traditionally known for causing ulcers, may help prevent the buildup of proteins linked to Alzheimer's disease, offering a potential new therapeutic approach, though it is still in early experimental stages.
A study from Verona University suggests that drinking one espresso daily may reduce the risk of dementia, including Alzheimer's, by preventing the build-up of harmful tau proteins in the brain. The research, published in the Journal of Agricultural and Food Chemistry, highlights espresso's potential to dismantle these proteins, which are linked to cognitive decline. While the findings are promising, experts caution against drawing definitive conclusions, emphasizing the complexity of dementia and the need for a balanced lifestyle to mitigate risks.
Scientists at the University of Leeds have mapped the molecular structures of β-amyloid and tau proteins in an Alzheimer's patient's brain using cryo-electron tomography, revealing how these proteins disrupt brain functions. This breakthrough, published in Nature, could lead to new therapeutic approaches for neurological diseases.
Six experimental vaccines for Alzheimer's disease are currently in clinical trials, offering hope for the treatment and prevention of the condition. These vaccines target the toxic buildup of amyloid and tau proteins in the brain, which are believed to contribute to the development of Alzheimer's. Some of the vaccines have shown promising results in early trials, with high antibody response rates and potential slowing of cognitive decline. While these vaccines offer a more accessible and potentially cost-effective alternative to existing treatments, they are still a few years away from being available to patients. The development of vaccines represents a new frontier in Alzheimer's research and could have a significant impact on the treatment landscape for this devastating disease.
A study conducted by researchers from Washington University in St. Louis found that using sleeping pills, specifically suvorexant, may reduce the build-up of toxic proteins associated with Alzheimer's disease. The study involved 38 healthy adults who took suvorexant for two nights at a sleep clinic and experienced a slight decrease in amyloid-beta and tau proteins, which are known to accumulate in Alzheimer's. While the findings suggest a potential link between sleep and Alzheimer's markers, further research is needed to determine the long-term effects and risks of using sleeping pills as a preventive treatment for the disease.
Researchers have linked a sugar molecule in the blood with the abnormal build-up of the amyloid beta and tau proteins that characterize Alzheimer's. Spotting this particular molecule – bisected N-acetylglucosamine – could give doctors a way of recognizing a higher Alzheimer's risk level. If these findings develop into an Alzheimer's screening test, the researchers want to add other criteria, such as looking for the APOE4 gene, which is also associated with an increased risk of developing Alzheimer's.
A new study suggests that early menopause may increase the risk of developing Alzheimer’s disease, but hormone therapy (HT) could help offset that risk. The study analyzed brain scans from 193 women and 99 men who did not have a diagnosis of Alzheimer’s or other forms of dementia to look for signs of beta-amyloid plaques and tau proteins, two markers of Alzheimer’s disease. The findings suggested that women who went into menopause before age 40, from age 40 to 45, or who started hormone therapy more than five years after they started menopause had higher levels of tau in their brains. However, people who started HT around the time they began menopause didn’t have an increased risk for developing tau proteins in the brain, suggesting that the menopause treatment may temper the risk of developing Alzheimer’s disease.
A new study has found that early menopause may increase the risk of developing Alzheimer’s disease. Hormone therapy (HT) could help offset that risk. Women who went into menopause before age 40, from age 40 to 45, or who started hormone therapy more than five years after they started menopause had higher levels of tau in their brains. People who started HT around the time they began menopause didn’t have an increased risk for developing tau proteins in the brain, suggesting that the menopause treatment may temper the risk of developing Alzheimer’s disease.